ScienceMed®

Comparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis

Saúde Pública
Imagem de arquivo, ilustrativa — não é do estudo. Óvulo no cúmulo oóforo, em ovário humano. Ed Uthman · CC BY 2.0 · Wikimedia Commons

MetanáliseNível 1 · Evidência consolidadaGynecologic and obstetric investigation23 fev 20260 citações

Salvar

Resumo original em inglês

O que aconteceu

A systematic review and meta-analysis of published evidence was performed to compare the number of oocytes retrieved with recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) in a 2:1 ratio versus highly purified human menopausal gonadotropin (HP-hMG) alone from day 1 of OS. The literature search was conducted according to PRISMA guidelines (https://www.prisma-statement.org/) using Medline, EMBASE, Biosis, SciSearch, and TOXCENTER on STN. Studies were included if they reported on r-hFSH:r-hLH in a 2:1 ratio versus HP-hMG alone, both administered from day 1 of OS, and the results for the number of oocytes retrieved were presented for both interventions. Data were extracted from the full articles independently by two reviewers (J.-E.S. and B.H.). Results were analyzed using a random-effects meta-analysis model. Any potential risk of bias was assessed using the ROBINS-I tool. Secondary outcomes were the number of mature (MII) oocytes, clinical pregnancy rate, ongoing pregnancy rate, and live birth rate.

O que encontraram

Six studies were included in the meta-analysis (5,287 cycles): four non-interventional studies, one non-interventional cross-over study, and one randomized controlled trial. The number of oocytes per cycle was significantly higher in women treated with r-hFSH:r-hLH 2:1 compared with those treated with HP-hMG alone (mean difference 1.43, 95% confidence interval [CI]: 0.18-2.69; p = 0.025). Clinical pregnancy rate per started cycle was significantly higher with r-hFSH:r-hLH 2:1 compared with HP-hMG (rate ratio 1.18, 95% CI: 1.06-1.33; p = 0.004; five studies). There were insufficient data to draw any firm conclusions on the other secondary outcomes.

Por que isso importa

The higher number of oocytes retrieved with r-hFSH:r-hLH is a pertinent finding, owing to the well-established positive association between oocyte number and reproductive outcomes. Although we report a higher clinical pregnancy rate for r-hFSH:r-hLH 2:1, limited data prevented us from drawing firm conclusions regarding live birth outcomes. .

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Comparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis

Michael H Dahan, Juan-Enrique Schwarze, Shiv Shanker Gupta, Brooke Hayward, Robert Fischer, Sandro C Esteves, Ming-Jer Chen, Kaylen M Silverberg, Luis Guzman, Daniele Santi et al.

Descritores MeSH

  • Follicle Stimulating Hormone
  • Fertilization in Vitro
  • Luteinizing Hormone
  • Sperm Injections, Intracytoplasmic
  • Follicle Stimulating Hormone, Human
  • Menotropins
  • Ovulation Induction
  • Oocyte Retrieval
  • Humans
  • Pregnancy

Veja também

Estudos relacionados